Experimental drug trial offers hope for critically ill children with uncontrollable low blood pressure

This study is testing whether adding the drug Angiotensin II (brand name Giapreza) to standard treatments helps children with severe, life-threatening low blood pressure that hasn't responded to fluids and other medications. Researchers will enroll 30 critically ill children under 18 to see if the drug safely improves blood pressure and reduces the need for other strong medications. The study will closely monitor children's vital signs, organ function, and any side effects for 28 days.